Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2022-03-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司2022年限制性股票激励计划（草案）
Regulatory Filings Classification · 95% confidence The document is a detailed draft of a 2022 restricted stock incentive plan for Jiangsu Haobo Biopharmaceutical Co., Ltd. It includes extensive information about the stock incentive plan, such as the purpose, legal basis, management, scope, stock source, quantity, allocation, effective period, grant date, vesting arrangements, price determination, and conditions for granting and vesting. The document is regulatory in nature, related to equity incentive plans, and is not a financial report, earnings release, or management discussion. It is not a brief announcement but a comprehensive plan document. This type of document fits best under the category of Regulatory Filings (RNS) because it is a regulatory disclosure about a stock incentive plan, which does not fall under other specific categories like Capital/Financing Update or Board/Management Information. The document length is substantial and contains detailed regulatory and legal information about the incentive plan, consistent with RNS filings in Chinese markets.
2022-03-18 Chinese
江苏浩欧博生物医药股份有限公司独立董事关于公司第二届董事会第十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the company's 2022 restricted stock incentive plan draft and related matters discussed at the 14th meeting of the second board of directors. It discusses compliance with laws and regulations, qualifications of incentive recipients, and the scientific and reasonable nature of performance indicators. The document is a formal opinion related to board meeting matters, specifically about a stock incentive plan, and does not contain financial statements or earnings data. It is not an annual report, audit report, earnings release, or any financial report. It is also not a simple announcement or certification. The content fits best under Board/Management Information (MANG) as it relates to board meeting decisions and opinions on management incentive plans.
2022-03-18 Chinese
江苏浩欧博生物医药股份有限公司2022年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as an implementation and assessment management method for a 2022 restricted stock incentive plan by Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the purpose, principles, scope, assessment institutions, performance indicators, assessment periods, procedures, and management of results related to the company's stock incentive plan. The content focuses on governance and management of the stock incentive plan rather than financial results, audit, or regulatory filings. It is a governance-related document concerning internal rules and incentive mechanisms approved by the board and shareholders. The document length is 4301 characters, which is relatively short but contains substantive content about governance and management of stock incentives, not just an announcement or summary. Therefore, it fits best under Governance Information (CGR) as it details the company's internal governance practices related to stock incentives.
2022-03-18 Chinese
上海荣正投资咨询股份有限公司关于江苏浩欧博生物医药股份有限公司2022年限制性股票激励计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to a 2022 Restricted Stock Incentive Plan (draft) for Jiangsu Haoubo Biopharmaceutical Co., Ltd. It contains detailed explanations of the stock incentive plan, including definitions, scope, allocation, pricing, vesting conditions, and legal compliance. The document is not a full annual or interim financial report, nor is it an earnings release or a regulatory filing announcement. It is a specialized advisory report on a stock incentive plan, which is a form of capital/financing update related to equity incentives and share issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification.
2022-03-18 Chinese
江苏浩欧博生物医药股份有限公司第二届监事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the approval of a restricted stock incentive plan and related management measures. It includes details about the meeting, voting results, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial performance data, nor is it a transcript, presentation, or report publication announcement. It is a formal announcement of board/management decisions related to company governance and incentive plans. Therefore, it fits best under Board/Management Information (MANG). The document length is short (2106 characters), and it is not merely an announcement of a report but a substantive board resolution announcement.
2022-03-18 Chinese
江苏浩欧博生物医药股份有限公司关于独立董事公开征集委托投票权的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is an announcement by Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the public solicitation of proxy voting rights by an independent director for the 2022 first extraordinary general meeting of shareholders. It details the solicitation process, voting instructions, and the agenda items related to a restricted stock incentive plan. The document is procedural and relates to the solicitation of votes for shareholder meeting agenda items, not the meeting materials themselves or the voting results. It is not a full report, financial statement, or earnings release. It fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). Since it is about soliciting proxy votes before the meeting, it aligns best with Proxy Solicitation & Information Statement (PSI).
2022-03-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.